AbbVie recently received FDA approvals for Decnupaz and Skinvive by Juvederm, enhancing its product portfolio. The company also reported positive Phase 3 trial results for chronic lymphocytic leukemia treatment, supporting future oncology growth. Additionally, AbbVie's drug Venclexta generated $770 million in Q1 revenue, marking significant year-over-year and quarterly increases. These developments reinforce AbbVie's strong position in immunology and oncology markets despite competitive pressures.
AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash. Apogee is developing a long-acting drug for atopic dermatitis that blocks the IL-13 protein causing eczema. The drug is expected to enter Phase 3 trials later this year, pote...
The Schwab U.S. Dividend Equity ETF (SCHD) provides investors with a low-cost, diversified portfolio of U.S. companies known for consistent dividend growth, making it an attractive option for those seeking a stable and growing income stream in retire...
AbbVie announced a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to shareholders of record as of July 15, 2026. Since its founding in 2013, AbbVie has increased its dividend by over 330%, reflecting its strong commitment to ...
Retirees with $500,000 to invest in dividend ETFs face a choice between Vanguard Dividend Appreciation ETF (VIG) and Schwab U.S. Dividend Equity ETF (SCHD). VIG offers lower current yield (~1.7%-1.8%) but focuses on companies with long histories of d...
In choppy markets, income investors favor companies that consistently raise dividends, and three Dividend Kings—Coca-Cola, Procter & Gamble, and AbbVie—stand out in 2026. Coca-Cola marked its 63rd consecutive year of dividend increases, supported by ...
